Minimal Impact of Clinical Stage on Prostate Cancer Prognosis Among Contemporary Patients With Clinically Localized Disease

Journal of Urology

Volumn 184, Issue 1, 2010, Pages 114-119

  Reese, Adam C ^a   Cooperberg, Matthew R ^a   Carroll, Peter R ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

neoplasm staging; prognosis; prostatectomy; prostatic neoplasms

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER LOCALIZATION; CANCER PATIENT; CANCER RECURRENCE; CANCER STAGING; CONTROLLED STUDY; GLEASON SCORE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PRIORITY JOURNAL; PROGNOSIS; PROSTATE ADENOCARCINOMA; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY;

BIOPSY; HUMANS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; REGISTRIES; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 77953119933     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2010.03.025     Document Type: Article

References (30)

1. Greene F.L. AJCC Cancer Staging Manual. 6th ed. (2002), Springer-Verlag, New York xiv
2. Partin A.W., Yoo J., Carter H.B., et al. The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer. J Urol 150 (1993) 110
3. Cooperberg M.R., Pasta D.J., Elkin E.P., et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol 173 (2005) 1938
4. Shariat S.F., Karakiewicz P.I., Roehrborn C.G., et al. An updated catalog of prostate cancer predictive tools. Cancer 113 (2008) 3075
5. Stephenson A.J., Scardino P.T., Eastham J.A., et al. Preoperative nomogram predicting the 10-year probability of prostate cancer recurrence after radical prostatectomy. J Natl Cancer Inst 98 (2006) 715
6. D'Amico A.V., Whittington R., Malkowicz S.B., et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280 (1998) 969
7. Jani A.B., Vaida F., Hanks G., et al. Changing face and different countenances of prostate cancer: racial and geographic differences in prostate-specific antigen (PSA), stage, and grade trends in the PSA era. Int J Cancer 96 (2001) 363
8. Cooperberg M.R., Lubeck D.P., Mehta S.S., et al. Time trends in clinical risk stratification for prostate cancer: implications for outcomes (data from CaPSURE). J Urol 170 (2003) S21
9. Cooperberg M.R., Broering J.M., Litwin M.S., et al. The contemporary management of prostate cancer in the United States: lessons from the Cancer of the Prostate Strategic Urologic Research Endeavor (CapSURE), a national disease registry. J Urol 171 (2004) 1393
10. Cookson M.S., Aus G., Burnett A.L., et al. Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: the American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel report and recommendations for a standard in the reporting of surgical outcomes. J Urol 177 (2007) 540
11. Swanson G.P., Riggs M., and Hermans M. Pathologic findings at radical prostatectomy: risk factors for failure and death. Urol Oncol 25 (2007) 110
12. Bostwick D.G. Staging prostate cancer-1997: current methods and limitations. Eur Urol 32 (1997) 2
13. Freedland S.J., Partin A.W., Epstein J.I., et al. Biochemical failure after radical prostatectomy in men with pathologic organ-confined disease: pT2a versus pT2b. Cancer 100 (2004) 1646
14. Hong S.K., Han B.K., Chung J.S., et al. Evaluation of pT2 subdivisions in the TNM staging system for prostate cancer. BJU Int 102 (2008) 1092
15. Armatys S.A., Koch M.O., Bihrle R., et al. Is it necessary to separate clinical stage T1c from T2 prostate adenocarcinoma?. BJU Int 96 (2005) 777
16. Billis A., Magna L.A., Watanabe I.C., et al. Are prostate carcinoma clinical stages T1c and T2 similar?. Int Braz J Urol 32 (2006) 165
17. Ghavamian R., Blute M.L., Bergstralh E.J., et al. Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy. Urology 54 (1999) 105
18. Ramos C.G., Carvalhal G.F., Smith D.S., et al. Clinical and pathological characteristics, and recurrence rates of stage T1c versus T2a or T2b prostate cancer. J Urol 161 (1999) 1525
19. Gosselaar C., Roobol M.J., van den Bergh R.C., et al. Digital rectal examination and the diagnosis of prostate cancer-a study based on 8 years and three screenings within the European Randomized Study of Screening for Prostate Cancer (ERSPC), Rotterdam. Eur Urol 55 (2009) 139
20. Gosselaar C., Kranse R., Roobol M.J., et al. The interobserver variability of digital rectal examination in a large randomized trial for the screening of prostate cancer. Prostate 68 (2008) 985
21. Sotelo R.J., Mora K.E., Perez L.H., et al. Assay standardization bias: different prostate cancer detection rates and clinical outcomes resulting from different assays for free and total prostate-specific antigen. Urology 69 (2007) 1143
22. Bruun L., Becker C., Hugosson J., et al. Assessment of intra-individual variation in prostate-specific antigen levels in a biennial randomized prostate cancer screening program in Sweden. Prostate 65 (2005) 216
23. Allsbrook Jr. W.C., Mangold K.A., Johnson M.H., et al. Interobserver reproducibility of Gleason grading of prostatic carcinoma: urologic pathologists. Hum Pathol 32 (2001) 74
24. Cagiannos I., Karakiewicz P., Eastham J.A., et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 170 (2003) 1798
25. Kattan M.W., Eastham J.A., Stapleton A.M., et al. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst 90 (1998) 766
26. Koh H., Kattan M.W., Scardino P.T., et al. A nomogram to predict seminal vesicle invasion by the extent and location of cancer in systematic biopsy results. J Urol 170 (2003) 1203
27. Ohori M., Kattan M.W., Koh H., et al. Predicting the presence and side of extracapsular extension: a nomogram for staging prostate cancer. J Urol 171 (2004) 1844
28. Stephenson A.J., Kattan M.W., Eastham J.A., et al. Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol 27 (2009) 4300
29. Thompson I., Thrasher J.B., Aus G., et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 177 (2007) 2106
30. Cooperberg M.R., Cowan J., Broering J.M., et al. High-risk prostate cancer in the United States, 1990-2007. World J Urol 26 (2008) 211